HOME >> BIOLOGY >> NEWS
The Molecular Profiling Institute named US provider of genetic breast cancer test

Phoenix, AZ, December 8, 2004--The Molecular Profiling Institute (MPI), today announced that it is the sole source provider in the United States for MammaPrint. MammaPrint is a prognostic test developed by Agendia that helps identify how a breast cancer patient's tumor will behave. MPI in collaboration with the Netherlands-based Agendia, and AmeriPath will offer MammaPrint through physician referral to breast cancer patients nationwide beginning in January 2005.

MammaPrint employs gene expression profiling to assess the recurrence risk in breast cancer patients. Oncologists receive detailed prognostic information on women with primary invasive breast cancer aged 55 years or younger who are lymph node negative with either a positive or negative estrogen receptor status. Taken together with a patient's clinical information this test may provide valuable assistance for oncologists in formulating tailor-made treatment plans.

Approximately 70 percent of the 250,000 patients diagnosed annually with breast cancer are stage I and II. Nearly 50 percent of affected women are under age 60. The test has the potential to add positively to the clinical decisions influencing nearly 70,000 breast cancer patients per year.

Using the MammaPrint microarray assay, MPI can determine which genes are expressed in a breast cancer patient's tumor. The tumor is then classified as "good" prognosis or "poor" prognosis. The results allow oncologists to implement a more effective and personalized treatment plan.

Typically, oncologists use several clinical factors --age, estrogen receptor status, tumor size and grade-- to determine how a patient's tumor will behave and how best to intervene. When compared to these clinical factors, the MammaPrint test has been shown to provide the most comprehensive prognostic information assessing the development of future metastases.

A patient-tailored treatment plan based on the genetics of the tumor combined with sta
'"/>

Contact: Galen Perry
gperry@tgen.org
602-377-4734
The Translational Genomics Research Institute
8-Dec-2004


Page: 1 2 3

Related biology news :

1. Molecular detectors may refine cancer treatment
2. Story ideas from Molecular & Cellular Proteomics
3. 2007 Image of the Year: Molecular imaging relates human brain chemistry to aggressive behavior
4. Molecular motors may speed nutrient processing
5. Molecular rendezvous caught on camera
6. Molecular tools make the cut
7. Genomatix and Molecular Connections form strategic partnership
8. Molecular motors and brakes work together in cells
9. Molecular link between inflammation and cancer discovered
10. Molecular on/off switch controls immune defenses against viruses
11. Molecular marker on stem cells aids research, perhaps therapies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2020)... ... June 11, 2020 , ... ... a significant expansion of its forensic genealogy team. Bode’s Forensic Genealogy Service ... proven forensic genealogy and DNA analysis methods. The team has added experienced genealogists, ...
(Date:6/5/2020)... ... 04, 2020 , ... “Although we are disappointed to have to make this ... and the public. We remain committed to creating a global platform to showcase ... Julie Sutcliffe, President of WMIS. , The abstract deadline for the ...
(Date:5/28/2020)... ... , ... CrucialTrak, a global designer and manufacturer of biometric access control systems, ... market and sell its complete line of biometric readers and access gates . ... solutions . , Brett Mason, CrucialTrak’s Director of Channel Sales for the Americas ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... 2020 , ... MedShift , a leading medical technology ... obstacles created as a result of COVID-19. As a provider at the forefront ... and medical manufacturers by expanding access to device offerings, technology services, and marketing ...
(Date:6/28/2020)... HILL, Conn. (PRWEB) , ... June 25, 2020 ... ... company formed to advance photodynamic therapy for treating cancer, today announced the company ... New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals ... be presented June 22-24 during the American Association for Cancer Research Virtual meeting. ... profiles the potent, consistent single agent activity in KEAP1 mutant tumor models of ...
(Date:6/11/2020)... (PRWEB) , ... June 09, 2020 , ... ... the release of the NEON Micro-Tracer Solution, a highly accurate, contact ... COVID-19 virus in the workplace. Contact tracing, a core disease control measure, is ...
Breaking Biology Technology:
Cached News: